HUTCHMED (China) Limited (HCM)

HUTCHMED (China) Limited has introduced its next-generation Antibody-Targeted Therapy Conjugate (ATTC) platform and shared major pipeline updates at its...

HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World...

HUTCHMED (China) has announced that Chief Executive Officer Dr Weiguo Su will take a leave of absence due to...

HUTCHMED has completed patient enrollment for its Phase III SANOVO trial evaluating ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) as a...

HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting,...

HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET...